NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study_老虎社区_美港股上老虎

NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study

Benzinga2021-05-24

NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

139

Nemesis82
·2021-05-25
Ok
回复
1
举报
Khoogl
·2021-05-25
Latest
回复
1
举报
收起
- MamaProfit:
  need reply
  2021-05-25
  回复
  举报
- Nemesis82:
  OK
  2021-05-25
  回复
  举报
HiDaya
·2021-05-25
Respond buddy
回复
4
举报
GoG
·2021-05-25
Oh..
回复
5
举报
收起
- GoG:
  oh
  2021-05-25
  回复
  举报
Sos
·2021-05-25
Sad 😂
回复
4
举报
40c9acb5
·2021-05-25
Pls like and comment
回复
5
举报
收起
- BruceInvests:
  Like & comment back pls
  2021-05-25
  回复
  举报
ryanlow
·2021-05-25
wow
回复
4
举报
banchin
·2021-05-25
Please give me comments and like
回复
2
举报
收起
- IsleofSkye:
  Done. Pls comment back
  2021-05-25
  回复
  举报
- banchin:
  Sure
  2021-05-25
  回复
  举报
MarcusLiong
·2021-05-25
S&L pls
回复
2
举报
收起
- AndreR93:
  Reply pls
  2021-05-25
  回复
  举报
Seuna
·2021-05-25
Like and comment please
回复
点赞
举报
收起
- AndreR93:
  Reply pls
  2021-05-25
  回复
  举报
HKhin
·2021-05-25
Wah 39%
回复
1
举报
收起
- AndreR93:
  Reply pls
  2021-05-25
  回复
  举报
KuehBulu
·2021-05-25
Pls like n comment 😊
回复
1
举报
收起
- KinKin:
  Sure
  2021-05-26
  回复
  举报
- AndreR93:
  Reply pls
  2021-05-25
  回复
  举报
- KinKin:
  Pls reply
  2021-05-25
  回复
  举报
Rocket2ocean
·2021-05-25
Like please! 😀
回复
2
举报
收起
- KinKin:
  Pls Reply
  2021-05-25
  回复
  举报
Natadecoco
·2021-05-25
Good
回复
点赞
举报
Jaywei
·2021-05-25
Cool
回复
4
举报
收起
- Rocket2ocean:
  Yay!
  2021-05-25
  回复
  举报
tangtkh
·2021-05-24
Like and comment
回复
4
举报
OO_898
·2021-05-24
Like
回复
1
举报
donnie991
·2021-05-24
First to like and commend
回复
3
举报
收起
- ckww:
  Ok
  2021-05-24
  回复
  举报
- KuehBulu:
  ok
  2021-05-25
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2137155575?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-05-24 23:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2137155575","market":"us","top_or_hot":-1,"title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","media":"Benzinga","content":"<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">网页链接</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NGM","symbol_name":"NGM Biopharmaceuticals Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","article_id":"2137155575","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","pubTimestamp":1621868714,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"translate_title":"NASH研究中期Aldafermin不及格后NGM股价暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGM":0.9,"MRK":0.6},"content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":131755684,"gmtCreate":1621898790848,"gmtModify":1634185786823,"author":{"id":"3582661821553489","authorId":"3582661821553489","authorIdStr":"3582661821553489","name":"Nemesis82","avatar":"https://static.tigerbbs.com/dfb31dceb8c850482302d788e9796155","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3582661821553489"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131755684","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131724417,"gmtCreate":1621898232039,"gmtModify":1634185794652,"author":{"id":"3566032787349185","authorId":"3566032787349185","authorIdStr":"3566032787349185","name":"Khoogl","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566032787349185"},"htmlText":"Latest&nbsp;","listText":"Latest&nbsp;","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/131724417","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4436231,"gmtCreate":1621898664458,"gmtModify":1635400301055,"authorId":3577432235687566,"author":{"id":3577432235687566,"authorId":3577432235687566,"name":"MamaProfit","avatar":"https://static.tigerbbs.com/71c384811ff2abe860a7f1c6804b88b0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131724417,"type":1,"supId":0,"prevId":0,"content":"need reply","text":"need reply","html":"need reply"},{"id":4436263,"gmtCreate":1621898775888,"gmtModify":1635400298431,"authorId":3582661821553489,"author":{"id":3582661821553489,"authorId":3582661821553489,"name":"Nemesis82","avatar":"https://static.tigerbbs.com/dfb31dceb8c850482302d788e9796155","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131724417,"type":1,"supId":4436231,"prevId":0,"content":"OK","text":"OK","html":"OK"}],"langContent":"EN"},{"id":131726525,"gmtCreate":1621898107367,"gmtModify":1634185797477,"author":{"id":"3584409189861115","authorId":"3584409189861115","authorIdStr":"3584409189861115","name":"HiDaya","avatar":"https://static.tigerbbs.com/bb87d9a1b7333340c5c703cd08909596","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3584409189861115"},"htmlText":"Respond buddy","listText":"Respond buddy","text":"Respond buddy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131726525","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131721277,"gmtCreate":1621897950599,"gmtModify":1634185799249,"author":{"id":"3570186020309805","authorId":"3570186020309805","authorIdStr":"3570186020309805","name":"GoG","avatar":"https://static.tigerbbs.com/1c9fbe31d027bcf439a17955df60352f","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3570186020309805"},"htmlText":"Oh..","listText":"Oh..","text":"Oh..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131721277","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4436073,"gmtCreate":1621897961933,"gmtModify":1635400314417,"authorId":3570186020309805,"author":{"id":3570186020309805,"authorId":3570186020309805,"name":"GoG","avatar":"https://static.tigerbbs.com/1c9fbe31d027bcf439a17955df60352f","vip":1,"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131721277,"type":1,"supId":0,"prevId":0,"content":"oh","text":"oh","html":"oh"}],"langContent":"EN"},{"id":131765022,"gmtCreate":1621897593966,"gmtModify":1634185805145,"author":{"id":"3575112879260258","authorId":"3575112879260258","authorIdStr":"3575112879260258","name":"Sos","avatar":"https://static.tigerbbs.com/7f120257600b00c1840d676f817362d4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3575112879260258"},"htmlText":"Sad 😂","listText":"Sad 😂","text":"Sad 😂","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131765022","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131780683,"gmtCreate":1621896421942,"gmtModify":1634185819424,"author":{"id":"3581823222182692","authorId":"3581823222182692","authorIdStr":"3581823222182692","name":"40c9acb5","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581823222182692"},"htmlText":"Pls like and comment&nbsp;","listText":"Pls like and comment&nbsp;","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131780683","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4435788,"gmtCreate":1621896434357,"gmtModify":1635400338845,"authorId":3561411454660142,"author":{"id":3561411454660142,"authorId":3561411454660142,"name":"BruceInvests","avatar":"https://static.tigerbbs.com/10405fa513601c345286a388991d53d8","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131780683,"type":1,"supId":0,"prevId":0,"content":"Like &amp; comment back pls","text":"Like &amp; comment back pls","html":"Like &amp; comment back pls"}],"langContent":"EN"},{"id":131715020,"gmtCreate":1621896154360,"gmtModify":1634185822014,"author":{"id":"3578697890023823","authorId":"3578697890023823","authorIdStr":"3578697890023823","name":"ryanlow","avatar":"https://static.tigerbbs.com/ef1ede5b3203c87007bdaeb19d8327f4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578697890023823"},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131715020","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131739164,"gmtCreate":1621894869758,"gmtModify":1634185833969,"author":{"id":"3582063342503280","authorId":"3582063342503280","authorIdStr":"3582063342503280","name":"banchin","avatar":"https://static.tigerbbs.com/5c4c72eded6f6ba8a8c66bbf3cd0e90c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3582063342503280"},"htmlText":"Please give me comments and like&nbsp;","listText":"Please give me comments and like&nbsp;","text":"Please give me comments and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/131739164","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4435868,"gmtCreate":1621896938914,"gmtModify":1635400332509,"authorId":3568855588230949,"author":{"id":3568855588230949,"authorId":3568855588230949,"name":"IsleofSkye","avatar":"https://static.tigerbbs.com/67513c367fa2b32512713968a36dcf7d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131739164,"type":1,"supId":0,"prevId":0,"content":"Done. Pls comment back","text":"Done. Pls comment back","html":"Done. Pls comment back"},{"id":4444617,"gmtCreate":1621946986917,"gmtModify":1635399594131,"authorId":3582063342503280,"author":{"id":3582063342503280,"authorId":3582063342503280,"name":"banchin","avatar":"https://static.tigerbbs.com/5c4c72eded6f6ba8a8c66bbf3cd0e90c","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131739164,"type":1,"supId":4435868,"prevId":0,"content":"<u>Sure</u>","text":"<u>Sure</u>","html":"<u>Sure</u>"}],"langContent":"EN"},{"id":131472167,"gmtCreate":1621891668259,"gmtModify":1634185853118,"author":{"id":"3582475319067106","authorId":"3582475319067106","authorIdStr":"3582475319067106","name":"MarcusLiong","avatar":"https://static.tigerbbs.com/eeba4d6764b4f4171e912d25e2484fc8","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582475319067106"},"htmlText":"S&amp;L pls","listText":"S&amp;L pls","text":"S&L pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131472167","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4435353,"gmtCreate":1621893213117,"gmtModify":1635400370947,"authorId":3568230509761996,"author":{"id":3568230509761996,"authorId":3568230509761996,"name":"AndreR93","avatar":"https://static.tigerbbs.com/96d3de091542c3cf445343cfbe260aeb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131472167,"type":1,"supId":0,"prevId":0,"content":"Reply <u>pls</u>","text":"Reply <u>pls</u>","html":"Reply <u>pls</u>"}],"langContent":"EN"},{"id":131447188,"gmtCreate":1621890222344,"gmtModify":1634185858432,"author":{"id":"3569227954325701","authorId":"3569227954325701","authorIdStr":"3569227954325701","name":"Seuna","avatar":"https://static.tigerbbs.com/0bfb6c0f011a65d66aae3afb6132a82d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3569227954325701"},"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131447188","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4435359,"gmtCreate":1621893226444,"gmtModify":1635400370398,"authorId":3568230509761996,"author":{"id":3568230509761996,"authorId":3568230509761996,"name":"AndreR93","avatar":"https://static.tigerbbs.com/96d3de091542c3cf445343cfbe260aeb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131447188,"type":1,"supId":0,"prevId":0,"content":"Reply <u>pls</u>","text":"Reply <u>pls</u>","html":"Reply <u>pls</u>"}],"langContent":"EN"},{"id":131454729,"gmtCreate":1621883453461,"gmtModify":1634185863072,"author":{"id":"3571009840536733","authorId":"3571009840536733","authorIdStr":"3571009840536733","name":"HKhin","avatar":"https://static.tigerbbs.com/315ef1291b235114bbffd11981704437","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571009840536733"},"htmlText":"Wah 39%","listText":"Wah 39%","text":"Wah 39%","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131454729","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4435363,"gmtCreate":1621893233030,"gmtModify":1635400370070,"authorId":3568230509761996,"author":{"id":3568230509761996,"authorId":3568230509761996,"name":"AndreR93","avatar":"https://static.tigerbbs.com/96d3de091542c3cf445343cfbe260aeb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131454729,"type":1,"supId":0,"prevId":0,"content":"Reply <u>pls</u>","text":"Reply <u>pls</u>","html":"Reply <u>pls</u>"}],"langContent":"EN"},{"id":131428145,"gmtCreate":1621877755287,"gmtModify":1634185872386,"author":{"id":"3575830079167965","authorId":"3575830079167965","authorIdStr":"3575830079167965","name":"KuehBulu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3575830079167965"},"htmlText":"Pls like n comment 😊","listText":"Pls like n comment 😊","text":"Pls like n comment 😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/131428145","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4447175,"gmtCreate":1621963315703,"gmtModify":1631894227655,"authorId":3574428256060280,"author":{"id":3574428256060280,"authorId":3574428256060280,"name":"KinKin","avatar":"https://static.tigerbbs.com/b4f58c29c0c165071cb594bd19ce588a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131428145,"type":1,"supId":4434949,"prevId":0,"content":"Sure","text":"Sure","html":"Sure"},{"id":4435365,"gmtCreate":1621893238921,"gmtModify":1631894227645,"authorId":3568230509761996,"author":{"id":3568230509761996,"authorId":3568230509761996,"name":"AndreR93","avatar":"https://static.tigerbbs.com/96d3de091542c3cf445343cfbe260aeb","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131428145,"type":1,"supId":4434949,"prevId":0,"content":"Reply <u>pls</u>","text":"Reply <u>pls</u>","html":"Reply <u>pls</u>"},{"id":4434949,"gmtCreate":1621877806204,"gmtModify":1631894227635,"authorId":3574428256060280,"author":{"id":3574428256060280,"authorId":3574428256060280,"name":"KinKin","avatar":"https://static.tigerbbs.com/b4f58c29c0c165071cb594bd19ce588a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131428145,"type":1,"supId":0,"prevId":0,"content":"Pls reply","text":"Pls reply","html":"Pls reply"}],"langContent":"EN"},{"id":131485618,"gmtCreate":1621874607234,"gmtModify":1634185880626,"author":{"id":"3573564985836603","authorId":"3573564985836603","authorIdStr":"3573564985836603","name":"Rocket2ocean","avatar":"https://static.tigerbbs.com/871ff8b7f4e7fb157bec1151aefa3930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3573564985836603"},"htmlText":"Like please! 😀","listText":"Like please! 😀","text":"Like please! 😀","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131485618","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4434950,"gmtCreate":1621877817658,"gmtModify":1635400399297,"authorId":3574428256060280,"author":{"id":3574428256060280,"authorId":3574428256060280,"name":"KinKin","avatar":"https://static.tigerbbs.com/b4f58c29c0c165071cb594bd19ce588a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131485618,"type":1,"supId":0,"prevId":0,"content":"Pls Reply","text":"Pls Reply","html":"Pls Reply"}],"langContent":"EN"},{"id":131488229,"gmtCreate":1621874129161,"gmtModify":1634185882382,"author":{"id":"3578363505212666","authorId":"3578363505212666","authorIdStr":"3578363505212666","name":"Natadecoco","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578363505212666"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131488229","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131432534,"gmtCreate":1621872250928,"gmtModify":1634185893206,"author":{"id":"3572467863337252","authorId":"3572467863337252","authorIdStr":"3572467863337252","name":"Jaywei","avatar":"https://static.tigerbbs.com/beccce245458fd51f01db3fd362d9d9c","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3572467863337252"},"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/131432534","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4434770,"gmtCreate":1621874620683,"gmtModify":1635400410192,"authorId":3573564985836603,"author":{"id":3573564985836603,"authorId":3573564985836603,"name":"Rocket2ocean","avatar":"https://static.tigerbbs.com/871ff8b7f4e7fb157bec1151aefa3930","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131432534,"type":1,"supId":0,"prevId":0,"content":"Yay!","text":"Yay!","html":"Yay!"}],"langContent":"EN"},{"id":131430195,"gmtCreate":1621871772717,"gmtModify":1634185897750,"author":{"id":"3574817325947403","authorId":"3574817325947403","authorIdStr":"3574817325947403","name":"tangtkh","avatar":"https://static.tigerbbs.com/d9ad77ea495b2bbbfb9c10734b6f2fb0","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3574817325947403"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131430195","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131497780,"gmtCreate":1621871727840,"gmtModify":1634185898112,"author":{"id":"3582969710070724","authorId":"3582969710070724","authorIdStr":"3582969710070724","name":"OO_898","avatar":"https://static.tigerbbs.com/9fb3c360d5d7711641a868a144192fc7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3582969710070724"},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/131497780","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":131543490,"gmtCreate":1621869522310,"gmtModify":1631888693003,"author":{"id":"3574808590725358","authorId":"3574808590725358","authorIdStr":"3574808590725358","name":"donnie991","avatar":"https://static.tigerbbs.com/2aa0229645cabfe6cf50a23e765c1a12","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574808590725358"},"htmlText":"First to like and commend&nbsp;","listText":"First to like and commend&nbsp;","text":"First to like and commend","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/131543490","repostId":2137155575,"repostType":4,"repost":{"id":"2137155575","pubTimestamp":1621868714,"share":"https://www.laohu8.com/m/news/2137155575?lang=&edition=full","pubTime":"2021-05-24 23:05","market":"us","language":"en","title":"NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2137155575","media":"Benzinga","summary":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 s","content":"<ul><li><b><a href=\"https://laohu8.com/S/NGM\">NGM Biopharmaceuticals Inc</a></b>&nbsp;(NASDAQ: NGM)&nbsp;has reported results&nbsp;from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).</li><li>The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).</li><li>The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).</li><li>Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.</li><li>The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.</li><li>Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.</li><li>Additionally,&nbsp;<b>Merck &amp; Co Inc</b>&nbsp;(NYSE:&nbsp;MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.</li><li>NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.</li><li><b>Price Action:</b>&nbsp;NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.</li></ul>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNGM Stock Tumbles After Aldafermin Flunks In Mid-Stage NASH Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-24 23:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver ...</p>\n\n<a href=\"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NGM":"NGM Biopharmaceuticals Inc","MRK":"默沙东"},"source_url":"https://finance.yahoo.com/news/ngm-stock-tumbles-aldafermin-flunks-115014442.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2137155575","content_text":"NGM Biopharmaceuticals Inc (NASDAQ: NGM) has reported results from the 24-week Phase 2b ALPINE 2/3 study evaluating aldafermin in non-alcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis (F2/F3).The study did not meet its primary endpoint evaluating a dose-response improvement in liver fibrosis by more than 1 stage with no worsening of NASH at week 24 (p=0.55).The study did achieve statistical significance versus placebo on specific secondary endpoints, including NASH resolution (at the 3 mg dose) and multiple non-invasive measures of NASH, including liver fat content (at the 1 mg and 3 mg doses).Given the failure to meet the primary endpoint, the company has decided not to pursue Phase 3 development of aldafermin in F2/F3 NASH; instead will focus on its ophthalmology and oncology portfolio.The overall safety profile of aldafermin was consistent with prior studies and similar to that of placebo.Patients treated with aldafermin at all three doses studied in the trial demonstrated a comparable frequency of adverse events versus placebo.Additionally, Merck & Co Inc (NYSE: MRK) continues the global Phase 2b development of MK-3655, an FGFR1c/KLB agonistic antibody for NASH treatment, which NGM discovered under its collaboration with Merck.NGM will host a conference call and webcast with a slide presentation at 8:30 a.m. ET today.Price Action: NGM shares are trading 45.4% lower $15.5 in the premarket session on the last check Monday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4434182,"gmtCreate":1621869747795,"gmtModify":1635400449470,"authorId":3581586523786578,"author":{"id":3581586523786578,"authorId":3581586523786578,"name":"ckww","avatar":"https://static.tigerbbs.com/bc2cc1ef6533d547201ce880e7c04b9c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131543490,"type":1,"supId":0,"prevId":0,"content":"<u>Ok</u>","text":"<u>Ok</u>","html":"<u>Ok</u>"},{"id":4434941,"gmtCreate":1621877745583,"gmtModify":1635400399947,"authorId":3575830079167965,"author":{"id":3575830079167965,"authorId":3575830079167965,"name":"KuehBulu","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":131543490,"type":1,"supId":4434182,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":139,"commentSize":18,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}